PRAGMATIC META-ANALYSIS OF PROPORTIONAL ASSIST VENTILATION + VERSUS PRESSURE SUPPORT VENTILATION AND ITS IMPACT ON COST EFFECTIVENESS

R. Saunders¹, J. Davis¹, K.J. Bosma^{2,3}

1. Coreva Scientific, Königswinter, Germany; 2. Department of Medicine, University of Western Ontario, London, Canada; 3. London Health Sciences Centre, London, Ontario, Canada

Background

- Clinical studies of mechanical ventilation (MV) are often small with large uncertainty in outcomes [1,2]
- Meta-analysis provides a method to combine data into a single estimate of efficacy
- A meta-analysis of proportional assist ventilation+ (PAV+) versus pressure support ventilation (PSV) was recently undertaken but did not report on outcomes relevant to our cost-effectiveness model [3]
- A pragmatic meta-analysis was undertaken to provide estimates of efficacy and explore how data sources used impact on outcomes.



Methods

- A Markov-model of patient care from MV in the intensive care unit (ICU) through to discharge home or death was developed for the Canadian setting (**Fig.1**)
- Structured searches identified studies of PAV+ versus PSV that were then subject to meta-analysis
- Outcomes of interest were:
 - MV/ICU/hospital time
 - ICU/hospital mortality

Conclusion

- Efficacy data from individual trials as compared to meta-analysis substantially changed the numerical outcomes of the model
- However the interpretation



- The model was populated with efficacy inputs from either Canadian trials or meta-analysis estimates
- Outcome parameters:
 - 20 years time horizon
 - Costs in 2017 CAD
 - Quality-adjusted life years (QALYs) using EQ-5D
- A sensitivity analyses (n=2,000) was performed, using a willingness-to-pay (WTP) threshold of CAD 50,000 per QALY gained

Results

- Seven studies comparing PAV+ with PSV were identified (Fig.2)
- A total of 271 PAV+ patients and 253 PSV patients
- Meta-analysis included at least 4 studies for each outcome
- Heterogeneity was low (I2 \leq 24%) and PAV+ was associated with a significant reduction in time on MV (Fig. 2), in the ICU, and in hospital
- Using Canadian data the Cost of care and quality of life results were:
 - PSV: CAD 141,003 and 6.07 QALYs gained

remained the same: PAV+ is expected to be cost effective for mechanical ventilation in Canada



- PAV+: CAD 129,333 and 6.29 QALYs gained
- This makes PAV+ dominant.
- With meta-analysis data, PAV+ cost CAD 147,276 and accrued 6.98 QALYs over 20 years
- Therefore PAV+ was cost effective at CAD 21,100 per QALY gained
- The sensitivity analysis revealed that in the Canadian scenario 80% of simulations were under the WTP threshold, compared with 100% when using meta-analysis (Fig.3)

References

- 1. Bosma KJ, Read BA, Bahrgard Nikoo MJ, Jones PM, Priestap FA, Lewis JF. A Pilot Randomized Trial Comparing Weaning From Mechanical Ventilation on Pressure Support Versus Proportional Assist Ventilation. Crit Care Med. 2016;44(2):1-11. 2. Botha J, Green C, Carney I, Haji K, Gupta S, Tiruvoipati R. Proportional assist
- ventilation versus pressure support ventilation in weaning ventilation: a pilot randomised controlled trial. Crit Care Resusc. 2018;20(1):33-40.
- 3. Tirupakuzhi Vijayaraghavan BK, Hamed S, Jain A, et al. Evidence Supporting Clinical Use of Proportional Assist Ventilation: A Systematic Review and Meta-Analysis of Clinical Trials. J Intensive Care Med. January 2018:885066618769021.

Fig.3 [A] Sensitivity analysis for data from a single study

[B] Sensitivity analysis for data from a meta analysis

The diagonal line represents the willingness to pay threshold of 50,000 per QALY gained in both graphs. Dark red: domniated; light red: not cost-effective; light blue cost-effective; dark blue: dominant

PRS30 V19

ISPOR Europe 2019 2nd-6th of November **Copenhagen, Denmark**

Disclosure

RS is the owner and JD is an employee of Coreva Scientific, which received consultancy fees for this work. KB is the primary investigator on the PROMIZING study. Funded in part by Medtronic

CORZVA Scientific

Research funded by Medtronic Copyright © 2019